Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical ComparisonDefense World · Oct 12, 2026
Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewsWire · Oct 2, 2026
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia GravisGlobeNewsWire · Sep 29, 2026
Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewsWire · Sep 8, 2026
Cartesian Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 3, 2026
Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewsWire · Aug 7, 2026Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.88 | $0.46 | Beat |
| Apr 30, 2026 | -$0.84 | -$1.46 | Miss |
| Mar 9, 2026 | -$0.82 | -$1.38 | Miss |
| Nov 6, 2025 | -$0.81 | -$1.38 | Miss |
| Aug 7, 2025 | -$0.76 | $0.50 | Beat |
| May 8, 2025 | -$0.61 | -$0.68 | Miss |